Researchers have identified a previously unrecognised form of hormone therapy-resistant prostate cancer.
List view / Grid view
Memorial Sloan Kettering Cancer Center
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
A new study shows the ways in which epigenetic mechanisms control the activity of genes and may have an impact on the future treatment of certain cancers.
Researchers have developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognise and kill cancer cells.
Three-step pretargeted radioimmunotherapy offers safe and effective treatment for colorectal cancer...
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
17 June 2016 | By Victoria White, Digital Content Producer
Tri-I TDI will extend its current relationship with Takeda from the realm of small molecule discovery into the new research area of antibody drug discovery...
14 June 2016 | By Victoria White, Digital Content Producer
Stem cell generated functional pituitary tissue promoted normal hormone release when transplanted into rats with hypopituitarism...
13 June 2016 | By Victoria White, Digital Content Producer
Researchers have unveiled a novel radioimmunotherapy that resulted in complete remission of colorectal cancer in mouse models...